Sign inJoin waitlistJoin the waitlist

JH

John Hayslip

Hematology & Oncology

Credentials: · · ·

History

Medical University of South Carolina
2004–2005
Internal Medicine
Summa Health System
2001–2004
Doctor of Medicine
1997–2001

Research

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Blood · 2020 · 646 citations
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Journal of Clinical Oncology · 2019 · 557 citations
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC…
The Lancet Haematology · 2018 · 186 citations

JH
Jing-Zhou Hou
3 papers
Jonathan Friedberg
3 papers
TA
Tamer Ahmed
3 papers
Alberto Montero
2 papers · 1 as a fellow
Courtney DiNardo
2 papers
DS
Don Stevens
2 papers
JP
Jalajakshi Potluri
2 papers
Kieron Dunleavy
2 papers
Wyndham Wilson
2 papers
AL
Adam Lye
1 paper · 1 as a fellow
Alexandra Stefanovic
1 paper
Anand Karnad
1 paper

Grants

University of Kentucky Markey Cancer Center – Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.2M · University of Kentucky
2013–2018
Trial of Mesna to Prevent Doxorubicin-Induced Plasma Protein Oxidation and TNFa r
National Cancer Institute · R01
Contact PI · $188K · University of Kentucky
2010–2014

Clinical trials

High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL
Principal investigator · Completed · Phase 1
John Haslip
2009–2014
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
Principal investigator · Withdrawn · Phase 2
University of Kentucky
2008–2010